Estados Unidos · Plataformas y datos · Yahoo Finance

Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?

Publicado por Yahoo Finance · Estados Unidos hace 13 h

Krystal Biotech (KRYS) just paired a third quarter earnings beat with a new US$400 million share repurchase plan, giving investors fresh numbers on Vyjuvek demand and updated…

Leer el artículo completo en Yahoo Finance Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finance.yahoo.com)

Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?

También te puede interesar

Fabrinet (FN) Q1 2027 Earnings Call Transcript

Angel Oak Financial Strategies Income Term declares $0.115 dividend

Adani Group seeks $1.5 bln loan for data center expansion- Economic Times

Stock market after midterm elections: What S&P 500 history shows

Theta Gold Mines Reports Expiry of 12.6 Million Options

Amundi Funds - Income Opportunities A70 SGD MTD2 D

Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?

Compartir

También te puede interesar

Fabrinet (FN) Q1 2027 Earnings Call Transcript

Angel Oak Financial Strategies Income Term declares $0.115 dividend

Adani Group seeks $1.5 bln loan for data center expansion- Economic Times

Stock market after midterm elections: What S&P 500 history shows

Theta Gold Mines Reports Expiry of 12.6 Million Options

Amundi Funds - Income Opportunities A70 SGD MTD2 D